We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Seek More Detail in FDA Guidance on Increased Diversity in Clinical Trials
Drugmakers Seek More Detail in FDA Guidance on Increased Diversity in Clinical Trials
Drugmakers were generally supportive but raised some questions and concerns in comments on the FDA’s draft guidance on increasing diversity in clinical trials.